500 related articles for article (PubMed ID: 25037630)
1. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.
Noris M; Galbusera M; Gastoldi S; Macor P; Banterla F; Bresin E; Tripodo C; Bettoni S; Donadelli R; Valoti E; Tedesco F; Amore A; Coppo R; Ruggenenti P; Gotti E; Remuzzi G
Blood; 2014 Sep; 124(11):1715-26. PubMed ID: 25037630
[TBL] [Abstract][Full Text] [Related]
2. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
Galbusera M; Noris M; Gastoldi S; Bresin E; Mele C; Breno M; Cuccarolo P; Alberti M; Valoti E; Piras R; Donadelli R; Vivarelli M; Murer L; Pecoraro C; Ferrari E; Perna A; Benigni A; Portalupi V; Remuzzi G
Am J Kidney Dis; 2019 Jul; 74(1):56-72. PubMed ID: 30851964
[TBL] [Abstract][Full Text] [Related]
3. Modeling complement activation on human glomerular microvascular endothelial cells.
Stevens KH; Baas LM; van der Velden TJAM; Bouwmeester RN; van Dillen N; Dorresteijn EM; van Zuilen AD; Wetzels JFM; Michels MAHM; van de Kar NCAJ; van den Heuvel LP
Front Immunol; 2023; 14():1206409. PubMed ID: 37954621
[TBL] [Abstract][Full Text] [Related]
4. An
Gastoldi S; Aiello S; Galbusera M; Breno M; Alberti M; Bresin E; Mele C; Piras R; Liguori L; Santarsiero D; Benigni A; Remuzzi G; Noris M
Front Immunol; 2023; 14():1112257. PubMed ID: 36845135
[TBL] [Abstract][Full Text] [Related]
5. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.
Zuber J; Fakhouri F; Roumenina LT; Loirat C; Frémeaux-Bacchi V;
Nat Rev Nephrol; 2012 Nov; 8(11):643-57. PubMed ID: 23026949
[TBL] [Abstract][Full Text] [Related]
6. Rare genetic variant in the CFB gene presenting as atypical hemolytic uremic syndrome and immune complex diffuse membranoproliferative glomerulonephritis, with crescents, successfully treated with eculizumab.
Alfakeeh K; Azar M; Alfadhel M; Abdullah AM; Aloudah N; Alsaad KO
Pediatr Nephrol; 2017 May; 32(5):885-891. PubMed ID: 28210841
[TBL] [Abstract][Full Text] [Related]
7. Pathology after eculizumab in dense deposit disease and C3 GN.
Herlitz LC; Bomback AS; Markowitz GS; Stokes MB; Smith RN; Colvin RB; Appel GB; D'Agati VD
J Am Soc Nephrol; 2012 Jul; 23(7):1229-37. PubMed ID: 22677550
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
Wehling C; Amon O; Bommer M; Hoppe B; Kentouche K; Schalk G; Weimer R; Wiesener M; Hohenstein B; Tönshoff B; Büscher R; Fehrenbach H; Gök ÖN; Kirschfink M
Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
[TBL] [Abstract][Full Text] [Related]
9. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
Aradottir SS; Kristoffersson AC; Roumenina LT; Bjerre A; Kashioulis P; Palsson R; Karpman D
Front Immunol; 2021; 12():690821. PubMed ID: 34177949
[TBL] [Abstract][Full Text] [Related]
10. Complement Activation and Thrombotic Microangiopathies.
Palomo M; Blasco M; Molina P; Lozano M; Praga M; Torramade-Moix S; Martinez-Sanchez J; Cid J; Escolar G; Carreras E; Paules C; Crispi F; Quintana LF; Poch E; Rodas L; Goma E; Morelle J; Espinosa M; Morales E; Avila A; Cabello V; Ariceta G; Chocron S; Manrique J; Barros X; Martin N; Huerta A; Fraga-Rodriguez GM; Cao M; Martin M; Romera AM; Moreso F; Manonelles A; Gratacos E; Pereira A; Campistol JM; Diaz-Ricart M
Clin J Am Soc Nephrol; 2019 Dec; 14(12):1719-1732. PubMed ID: 31694864
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease.
Tran CL; Sethi S; Murray D; Cramer CH; Sas DJ; Willrich M; Smith RJ; Fervenza FC
Pediatr Nephrol; 2016 Apr; 31(4):683-7. PubMed ID: 26759144
[TBL] [Abstract][Full Text] [Related]
12. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
[TBL] [Abstract][Full Text] [Related]
13. Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome.
Magro CM; Momtahen S; Mulvey JJ; Yassin AH; Kaplan RB; Laurence JC
Am J Dermatopathol; 2015 May; 37(5):349-56; quiz 357-9. PubMed ID: 25893747
[TBL] [Abstract][Full Text] [Related]
14. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
Xie L; Nester CM; Reed AI; Zhang Y; Smith RJ; Thomas CP
Transplant Proc; 2012 Dec; 44(10):3037-40. PubMed ID: 23195022
[TBL] [Abstract][Full Text] [Related]
15. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.
Ueda Y; Miwa T; Ito D; Kim H; Sato S; Gullipalli D; Zhou L; Golla M; Song D; Dunaief JL; Palmer MB; Song WC
Kidney Int; 2019 Jul; 96(1):67-79. PubMed ID: 30910380
[TBL] [Abstract][Full Text] [Related]
16. Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab.
Besbas N; Gulhan B; Karpman D; Topaloglu R; Duzova A; Korkmaz E; Ozaltin F
Pediatr Nephrol; 2013 Jan; 28(1):155-8. PubMed ID: 22956028
[TBL] [Abstract][Full Text] [Related]
17. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
Vondrák K; Seeman T
Transplant Proc; 2018 Apr; 50(3):967-970. PubMed ID: 29661469
[TBL] [Abstract][Full Text] [Related]
18. COMPLEMENTing the diagnosis of aHUS.
Afshar-Kharghan V
Blood; 2014 Sep; 124(11):1699-700. PubMed ID: 25214194
[TBL] [Abstract][Full Text] [Related]
19. Disease Recurrence After Early Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome With Complement C3 I1157T Mutation.
Toyoda H; Wada H; Miyata T; Amano K; Kihira K; Iwamoto S; Hirayama M; Komada Y
J Pediatr Hematol Oncol; 2016 Apr; 38(3):e137-9. PubMed ID: 26840081
[TBL] [Abstract][Full Text] [Related]
20. Eculizumab and recurrent C3 glomerulonephritis.
Gurkan S; Fyfe B; Weiss L; Xiao X; Zhang Y; Smith RJ
Pediatr Nephrol; 2013 Oct; 28(10):1975-81. PubMed ID: 23689905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
